| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/02/2014 | US20140005147 Dna polymerase inhibitors composition and methods |
| 01/02/2014 | US20140005145 Combination breast cancer therapy with hsp90 inhibitory compounds |
| 01/02/2014 | US20140005144 Novel leukotriene receptor antagonist |
| 01/02/2014 | US20140005142 Method of stably treating incontinence using a bulking agent |
| 01/02/2014 | US20140005139 Cellooligosaccharide-containing composition |
| 01/02/2014 | US20140005137 Tissue maintenance |
| 01/02/2014 | US20140005136 Novel compounds and compositions and methods of use |
| 01/02/2014 | US20140005135 Stable formulations for parenteral injection of small molecule drugs |
| 01/02/2014 | US20140005134 GPBP-1 inhibition and its therapeutic use |
| 01/02/2014 | US20140005131 Active ingredient combinations of glucosyl glycerides and one or more preservatives |
| 01/02/2014 | US20140005122 Gemcitabine combination therapy |
| 01/02/2014 | US20140005105 Plasma anti-diabetic nucb2 peptide (pladin) and uses thereof |
| 01/02/2014 | US20140005103 Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| 01/02/2014 | US20140004212 Andrographis paniculata extract |
| 01/02/2014 | US20140004209 Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
| 01/02/2014 | US20140004207 Analgesic Apatitic Calcium-Phosphate Cement |
| 01/02/2014 | US20140004206 Methods and related compositions for reduction of fat and skin tightening |
| 01/02/2014 | US20140004205 Compositions and methods useful for ameliorating age related maladies |
| 01/02/2014 | US20140004203 Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| 01/02/2014 | US20140004202 Gamma-hydroxybutyric acid granules |
| 01/02/2014 | US20140004199 Drug carrier for tumor-targeted therapy, its preparation method and its use |
| 01/02/2014 | US20140004197 O/w-emulsions comprising semifluorinated alkanes |
| 01/02/2014 | US20140004192 Pharmaceutical formulations of indibulin and uses thereof |
| 01/02/2014 | US20140004190 Solid Dosage Forms of Bendamustine |
| 01/02/2014 | US20140004189 Modified release pharmaceutical compositions memantine |
| 01/02/2014 | US20140004188 Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
| 01/02/2014 | US20140004187 Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
| 01/02/2014 | US20140004186 Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin |
| 01/02/2014 | US20140004185 Pharmaceutical composition |
| 01/02/2014 | US20140004184 Coated tablet formulations and uses thereof |
| 01/02/2014 | US20140004183 Methods for treating cardiovascular disease in statin-tolerant subjects |
| 01/02/2014 | US20140004182 Methods for the treatment of sarcoidosis |
| 01/02/2014 | US20140004179 Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome |
| 01/02/2014 | US20140004177 Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof |
| 01/02/2014 | US20140004176 Delivery of treatments transdermally for fungal infections and other indications |
| 01/02/2014 | US20140004174 Selective inhibitors of histone deacetylase |
| 01/02/2014 | US20140004173 Production of multivesicular liposomes |
| 01/02/2014 | US20140004171 Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent |
| 01/02/2014 | US20140004166 Stable Emulsion for Prevention of Skin Irritation and Articles Using Same |
| 01/02/2014 | US20140004160 Orally effective methylphenidate extended release powder and aqueous suspension product |
| 01/02/2014 | US20140004157 Agent for delaying digestion and absorption of lipid |
| 01/02/2014 | US20140004140 Group b streptococcus vaccine |
| 01/02/2014 | US20140004122 Methods for treating or preventing cholesterol related disorders |
| 01/02/2014 | US20140004120 Novel anti-dr5 antibody |
| 01/02/2014 | US20140004113 Defensin-antigen fusion proteins |
| 01/02/2014 | US20140004111 Polycyclic agents for the treatment of respiratory syncytial virus infections |
| 01/02/2014 | US20140004104 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| 01/02/2014 | US20140004101 Smac peptidometics useful as iap inhibitors |
| 01/02/2014 | US20140004099 Dodecafluoropentane emulsion as a stroke and ischemia therapy |
| 01/02/2014 | US20140004093 Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution |
| 01/02/2014 | US20140004088 Identification and use of target genes for control of plant parasitic nematodes |
| 01/02/2014 | US20140004082 Methods for treating leukemia and disorders mediated by cbfbeta and runx1 proteins |
| 01/02/2014 | US20140004077 Method for treating cervical cancer |
| 01/02/2014 | US20140004068 Topical application of 1-hydroxyl 3,5-bis(4'hydroxyl styryl)benzene |
| 01/02/2014 | US20140004062 Composition including 3-bromo-4,5-dihydroxybenzaldehyde compound as effective component for protecting and treating skin cell aganist ultraviolet |
| 01/02/2014 | US20140004052 Aerosol Formulations Comprising Formoterol Fumarate Dihydrate |
| 01/02/2014 | US20140004042 Targeted delivery to human diseases and disorders |
| 01/02/2014 | CA2877083A1 Biodegradable drug delivery for hydrophobic compositions |
| 01/02/2014 | CA2820547A1 Rgd mimetic y-aapeptides and methods of use |
| 01/01/2014 | EP2679595A2 Di-(3-deoxy-3-1H-1,2,3-triazol-1-yl)-[beta]-D-galacto-pyranosyl)sulfane |
| 01/01/2014 | EP2679591A1 Thienopyridone derivatives useful as activators of AMPK |
| 01/01/2014 | EP2679586A1 Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same |
| 01/01/2014 | EP2679585A1 Glycine transport inhibitor |
| 01/01/2014 | EP2679584A1 Clathrate complex of cyclodextrin or arabinogalactan with 9-phenyl-sym-octahydroselenoxanthene |
| 01/01/2014 | EP2679580A1 Thioamide compound, method for producing thioamide compound, method for producing [(4r,6r)-6-aminoethyl-1,3-dioxane-4-yl]acetate derivative, and method for producing atorvastatin |
| 01/01/2014 | EP2679578A2 Preparation method and crystalline form of optical enantiomers of modafinil |
| 01/01/2014 | EP2679577A2 Preparation methods of crystalline forms of optical enantiomers of modafinil and pharmaceutical composition therof |
| 01/01/2014 | EP2679576A2 Preparation methods of forms of optical enantiomers of modafinil and pharmaceutical composition thereof |
| 01/01/2014 | EP2679574A1 Hydrated n-fullerene amino acids, method for producing the latter, and pharmaceutical compositions on the basis thereof |
| 01/01/2014 | EP2679302A1 Selective sorption agent for extracorporeal blood purification |
| 01/01/2014 | EP2679301A1 Extracorporeal perfusion device |
| 01/01/2014 | EP2679278A1 Dermatological compositions comprising heparan sulfate |
| 01/01/2014 | EP2679251A1 Adhesive compositions for medical use: single additive as both the thickening agent and the accelerator |
| 01/01/2014 | EP2679243A1 Co-precipitate of one or more stilbene polyphenols and their derivatives in lamellar anionic solids, it's applications and related preparation method |
| 01/01/2014 | EP2679230A1 Pharmaceutical formulation comprising compounds of the jasmonate family |
| 01/01/2014 | EP2679229A1 Composition for the treatment of hyperglycemic diseases |
| 01/01/2014 | EP2679228A1 Therapy using vitamin D repletion agent and vitamin D hormone replacement agent |
| 01/01/2014 | EP2679227A1 Nanoparticle containing prostaglandin i2 derivative |
| 01/01/2014 | EP2679226A1 Therapeutic agent for corneal sensory nerve damage containing semaphorin inhibitor as active ingredient |
| 01/01/2014 | EP2679225A1 Pharmaceutical compound with synergistic effect of direct catalase inhibitors and modulators for NO metabolism which lead to catalase destruction or extracellular superoxide anion production |
| 01/01/2014 | EP2679224A1 Nitro oleic acid modulation of type II diabetes |
| 01/01/2014 | EP2679223A1 Treatments using citrulline |
| 01/01/2014 | EP2679222A1 Use of oligomers of lactic acid in the treatment of gynaecological infections |
| 01/01/2014 | EP2679221A1 Method to enhance tissue regeneration |
| 01/01/2014 | EP2679220A1 Controlled porous osmotic pump tablet and the preparation method thereof |
| 01/01/2014 | EP2679219A1 Method for producing finely pulverized organic compound particle |
| 01/01/2014 | EP2678679A1 Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles |
| 01/01/2014 | EP2678431A1 Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine |
| 01/01/2014 | EP2678349A1 C-4" position substituted macrolide derivative |
| 01/01/2014 | EP2678347A1 Catalytic hydrogenolysis of a composition of a mixture of oligosaccharide precursors and uses thereof |
| 01/01/2014 | EP2678342A1 N-substituted oxazinopteridines and oxazinopteridinones |
| 01/01/2014 | EP2678341A1 Alpha helix mimetics and methods relating thereto |
| 01/01/2014 | EP2678339A1 Methods and compositions for treating -thalassemia and sickle cell disease |
| 01/01/2014 | EP2678337A1 2-amino-naphthyridine derivatives |
| 01/01/2014 | EP2678336A1 Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| 01/01/2014 | EP2678334A1 Anti-viral compounds |
| 01/01/2014 | EP2678332A2 Diaminopyrimidine derivatives and processes for the preparation thereof |
| 01/01/2014 | EP2678331A2 Diaminopyrimidine derivatives and processes for the preparation thereof |
| 01/01/2014 | EP2678330A1 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators) |
| 01/01/2014 | EP2678329A1 Triazolopyridine compounds as pim kinase inhibitors |